title: Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
abstract: BACKGROUND
  This secondary analysis aimed to identify predictors of low (<6 oocytes retrieved) and high ovarian response (>18 oocytes retrieved) in IVF patients undergoing controlled ovarian stimulation with corifollitropin alfa in a gonadotropin-releasing hormone (GnRH) antagonist protocol.
  
  
  METHODS
  Statistical model building for high and low ovarian response was based on the 150 μg corifollitropin alfa treatment group of the Pursue trial in infertile women aged 35-42 years (n = 694).
  
  
  RESULTS
  Multivariable logistic regression models were constructed in a stepwise fashion (P <0.05 for entry). 14.1 % of subjects were high ovarian responders and 23.2 % were low ovarian responders. The regression model for high ovarian response included four independent predictors: higher anti-Müllerian hormone (AMH) and antral follicle count (AFC) increased the risk, and higher follicle-stimulating hormone (FSH) levels and advancing age decreased the risk of high ovarian response. The regression model for low ovarian response also included four independent predictors: advancing age increased the risk, and higher AMH, higher AFC and longer menstrual cycle length decreased the risk of low ovarian response.
  
  
  CONCLUSIONS
  AMH, AFC and age predicted both high and low ovarian responses, FSH predicted high ovarian response, and menstrual cycle length predicted low ovarian response in a corifollitropin alfa/GnRH antagonist protocol.
  
  
  BACKGROUND
  NCT01144416 , Protocol P06029.
authors.affiliation: The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA, 23507-2007, USA. OehninSC@EVMS.edu.
authors.forename: Sergio
authors.initials: S
authors.lastname: Oehninger
authors.affiliation: School of Medicine, University of Glasgow, Glasgow, UK. Scott.Nelson@glasgow.ac.uk.
authors.forename: Scott M
authors.initials: SM
authors.lastname: Nelson
authors.affiliation: MSD BV, Oss, The Netherlands. pierre.verweij@gmail.com.
authors.forename: Pierre
authors.initials: P
authors.lastname: Verweij
authors.affiliation: Merck and Co., Inc., Kenilworth, NJ, USA. barbara.stegmann@merck.com.
authors.forename: Barbara J
authors.initials: BJ
authors.lastname: Stegmann
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000097:blood; D043373:Follicle Stimulating Hormone, Human / Q000494:pharmacology / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006727:Hormone Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D007986:Luteinizing Hormone / Q000097:blood; D054315:Oocyte Retrieval; D010053:Ovary / Q000187:drug effects*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D020554:Sperm Injections, Intracytoplasmic / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D043373:Follicle Stimulating Hormone, Human; D006727:Hormone Antagonists; C437186:follicle stimulating hormone, human, with HCG C-terminal peptide; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone